NICE positive for use of Eylea (aflibercept) to treat macular oedema secondary to branch retinal vein occlusion (BRVO)- Bayer HealthCare

The National Institute for Health and Care Excellence (NICE) has recommended Eylea (aflibercept) from Bayer HealthCare as a cost-effective first-line treatment option for adults with visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO). BRVO is caused by a blood clot in one of the branches of the main vein in the retina, which causes blood and fluid leaking beneath the macular oedema. If untreated, this can significantly impact a person�s vision, often resulting in sight loss.

NICE�s final appraisal determination is a change from their provisional decision, which refused to recommend Eylea as a first-line treatment. However, NICEnow coniders the treatment to be more clinically effective than existing first-line treatment laser photocoagulation.